Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Annexon, Inc. (ANNX)
USD5.70
+0.15 (+2.61%)
US NASDAQ Healthcare Biotechnology
Address
1400 Sierra Point Parkway 94005
Brisbane, CA, US
Brisbane, CA, US
CEO
Douglas E. Love
Website
annexonbio.com
IPO
2020-07-24
CIK 1528115 ISIN US03589W1027
Description
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD5.70
+0.15 (+2.61%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
1.17
Float Shares
128.16M
Free Float %
107.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.23% | -4.23% | -7.01% | +4.82% | +91.55% | +8.37% | +207.34% | -0.37% | -72.20% | -69.37% | -69.37% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (10 ratings, all time)
Buy
Price Targets & DCF
Current price
5.70
Low
7.00
+22.9%
Consensus
11.50
+101.9%
Median
11.50
+101.9%
High
16.00
+180.9%
DCF (Unlevered)
0.79
-86.2%
DCF (Levered)
0.88
-84.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 7 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
16.00
+180.9%
|
| All Time | 4 |
13.00
+128.3%
|
Quality scores
Altman Z-Score
0.19
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-32.7% Q1'26: +37.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: -3,727.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+12.9% Q1'26: +31.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.12× Q1'26: -0.14× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 5 EPS Ana. |
Dec 2027 7 Rev. Ana. 6 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 10.85M (-100.0%)
|
2.36M
432.7K – 5.99M
-78.2% YoY
|
44.07M
8.89M – 104.69M
+1,765.4% YoY
|
346.94M
339.35M – 354.54M
+687.3% YoY
|
651.66M
119.35M – 1.65B
+87.8% YoY
|
1.06B
194.28M – 2.69B
+62.8% YoY
|
| EBITDA |
-134.75M
|
-213.76M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-138.20M
|
-216.41M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-138.20M
est: -131.90M (-4.8%)
|
-206.69M
est: -208.55M (+0.9%)
|
-153.06M
-164.53M – -141.60M
+26.6% YoY
|
-100.61M
-141.16M – -60.07M
+34.3% YoY
|
90.00M
-120.03M – 279.35M
+189.5% YoY
|
205.60M
-12.73M – 616.12M
+128.4% YoY
|
418.58M
-25.91M – 1.25B
+103.6% YoY
|
| SGA |
34.63M
|
31.71M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.01
est: -0.95 (-5.8%)
|
-1.34
est: -1.38 (+2.8%)
|
-0.98
-1.06 – -0.91
+28.7% YoY
|
-0.78
-0.91 – -0.39
+20.2% YoY
|
0.29
-0.77 – 1.80
+137.3% YoY
|
1.33
-0.08 – 3.97
+352.9% YoY
|
2.70
-0.17 – 8.09
+103.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
48
Total invested
58.62M
Insider transactions (90d)
0
Beneficial owners (>5%)
34
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Abigail P. Johnson | 9.69M | 12.37% | — | — | 9.69M | — | IN | Delaware | 2024-01-10 | ↗ |
| 2 | FMR LLC | 9.69M | 12.37% | 9.68M | — | 9.69M | — | HC | Delaware | 2024-01-10 | ↗ |
| 3 | (1) BlackRock, Inc. | 7.65M | 7.20% | 7.52M | — | 7.65M | — | HC | Delaware | 2024-11-08 | ↗ |
| 4 | Muneer A. Satter | 5.03M | 10.40% | 5.03M | — | 5.03M | — | IN | — | 2022-07-18 | ↗ |
| 5 | Jeremy C. Green | 4.89M | 9.90% | — | 4.89M | — | 4.89M | HC, IN | United Kingdom | 2022-07-18 | ↗ |
| 6 | Redmile Group, LLC | 4.89M | 9.90% | — | 4.89M | — | 4.89M | IA, OO | Delaware | 2022-07-18 | ↗ |
| 7 | 2 | 4.87M | 6.20% | — | 4.87M | — | — | IN | — | 2024-02-12 | ↗ |
| 8 | BB Biotech AG | 4.68M | 5.20% | — | 4.68M | — | 4.68M | HC, CO | Switzerland | 2024-04-22 | ↗ |
| 9 | Biotech Growth N.V. | 4.68M | 5.20% | — | 4.68M | — | 4.68M | CO | Switzerland | 2024-04-22 | ↗ |
| 10 | Adage Capital Advisors, L.L.C. | 4.18M | 8.68% | — | 4.18M | — | — | OO | Delaware | 2022-07-18 | ↗ |
| 11 | Adage Capital Partners GP, L.L.C. | 4.18M | 8.68% | — | 4.18M | — | — | OO | Delaware | 2022-07-18 | ↗ |
| 12 | Adage Capital Partners, L.P. | 4.18M | 8.68% | — | 4.18M | — | — | PN | Delaware | 2022-07-18 | ↗ |
| 13 | Phillip Gross | 4.18M | 8.68% | — | 4.18M | — | — | IN | United States | 2022-07-18 | ↗ |
| 14 | Robert Atchinson | 4.18M | 8.68% | — | 4.18M | — | — | IN | United States | 2022-07-18 | ↗ |
| 15 | Redmile Biopharma Investments II, L.P. | 3.30M | 6.70% | — | 3.30M | — | 3.30M | PN | Delaware | 2022-07-18 | ↗ |
| 16 | Arsani William | 2.90M | 11.00% | — | 2.90M | — | 2.90M | HC, IN | Delaware | 2024-11-14 | ↗ |
| 17 | Logos GP LLC | 2.90M | 11.00% | — | 2.90M | — | 2.90M | OO | Delaware | 2024-11-14 | ↗ |
| 18 | Logos Global Management GP LLC | 2.90M | 11.00% | — | 2.90M | — | 2.90M | HC, OO | Delaware | 2024-11-14 | ↗ |
| 19 | Logos Global Management LP | 2.90M | 11.00% | — | 2.90M | — | 2.90M | IA, PN | Delaware | 2024-11-14 | ↗ |
| 20 | Logos Global Master Fund LP | 2.90M | 11.00% | — | 2.90M | — | 2.90M | PN | Delaware | 2024-11-14 | ↗ |
| 21 | Koh, Bong | 1.93M | 5.00% | — | 1.93M | — | — | IN | United States | 2022-06-23 | ↗ |
| 22 | Shah, Nimish | 1.93M | 5.00% | — | 1.93M | — | 1.93M | IN | United States | 2022-06-23 | ↗ |
| 23 | VHCP Co-Investment Holdings II, LLC | 1.93M | 5.00% | — | 1.93M | — | — | OO | Delaware | 2022-06-23 | ↗ |
| 24 | VHCP Co-Investment Holdings III, LLC | 1.93M | 5.00% | — | 1.93M | — | — | OO | Delaware | 2022-06-23 | ↗ |
| 25 | VHCP Management EG, LLC | 1.93M | 5.00% | — | 1.93M | — | 1.93M | OO | Delaware | 2022-06-23 | ↗ |
| 26 | VHCP Management II, LLC | 1.93M | 5.00% | — | 1.93M | — | 1.93M | OO | Delaware | 2022-06-23 | ↗ |
| 27 | VHCP Management III, LLC | 1.93M | 5.00% | — | 1.93M | — | 1.93M | OO | Delaware | 2022-06-23 | ↗ |
| 28 | Venrock Healthcare Capital Partners EG, L.P. | 1.93M | 5.00% | — | 1.93M | — | 1.93M | PN | Delaware | 2022-06-23 | ↗ |
| 29 | Venrock Healthcare Capital Partners II, L.P. | 1.93M | 5.00% | — | 1.93M | — | — | PN | Delaware | 2022-06-23 | ↗ |
| 30 | Venrock Healthcare Capital Partners III, L.P. | 1.93M | 5.00% | — | 1.93M | — | — | PN | Delaware | 2022-06-23 | ↗ |
| 31 | BVF II GP LLC | 1.33M | 3.50% | — | — | — | 1.33M | OO | Delaware | 2022-05-26 | ↗ |
| 32 | Biotechnology Value Fund II, L.P. | 1.33M | 3.50% | — | — | — | 1.33M | PN | Delaware | 2022-05-26 | ↗ |
| 33 | The reporting person disclaim beneficial ownership of the shares reported, which are owned of record | 1.23M | 2.59% | 1.23M | — | 1.23M | — | — | Switzerland | 2023-02-03 | ↗ |
| 34 | 2. | 10.00 | 4.90% | — | 2.33M | — | — | HC, OO | Delaware | 2023-02-27 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
48
-127 vs prev Q
New positions
18
Closed positions
137
Increased
35
Reduced
5
Put/Call ratio
0.00
Calls held
50.0K
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 750.0K +750.0K (+100.0%) | 3.77B +3.8B (+100.0%) | 0.50% +0.503 pp | 4.31% +4.305 pp | USD5.02 +0.0% | 1 qtrs NEW |
| 2 | FMR LLC | 10.22M -858.7K (-7.7%) | 51.32M +17.5M (+51.8%) | 6.86% -0.616 pp | 0.00% +0.001 pp | USD4.42 +13.6% | 22 qtrs — |
| 3 | REDMILE GROUP, LLC | 10.05M +3.8M (+59.5%) | 50.45M +31.2M (+162.6%) | 6.74% +2.492 pp | 3.72% +1.846 pp | USD12.76 -60.7% | 22 qtrs — |
| 4 | BVF INC/IL | 9.13M +2.1M (+30.4%) | 45.82M +24.5M (+114.6%) | 6.12% +1.402 pp | 1.54% +0.677 pp | USD4.65 +8.0% | 9 qtrs — |
| 5 | BLACKROCK, INC. | 8.96M +1.1M (+13.4%) | 44.98M +20.9M (+86.7%) | 6.01% +0.683 pp | 0.00% +0.000 pp | USD5.73 -12.4% | 6 qtrs — |
| 6 | VANGUARD GROUP INC | 7.75M +1.9M (+32.9%) | 38.92M +21.1M (+118.7%) | 5.20% +1.265 pp | 0.00% +0.000 pp | USD8.21 -38.9% | 22 qtrs — |
| 7 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 5.50M +4.0M (+266.7%) | 27.61M +23.0M (+503.5%) | 3.69% +2.677 pp | 0.04% +0.035 pp | USD4.48 +12.1% | 2 qtrs — |
| 8 | BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 5.25M +— (+0.0%) | 26.35M +10.3M (+64.6%) | 3.52% -0.019 pp | 2.02% +0.956 pp | USD14.33 -65.0% | 22 qtrs — |
| 9 | BELLEVUE GROUP AG | 5.16M +— (+0.0%) | 25.89M +10.2M (+64.6%) | 3.46% -0.019 pp | 0.49% +0.164 pp | USD5.72 -12.2% | 8 qtrs — |
| 10 | STATE STREET CORP | 4.65M +2.6M (+126.9%) | 23.35M +17.1M (+273.5%) | 3.12% +1.737 pp | 0.00% +0.001 pp | USD5.23 -4.0% | 22 qtrs — |
| 11 | AMERIPRISE FINANCIAL INC | 4.35M +2.2M (+98.4%) | 21.83M +15.1M (+226.5%) | 2.92% +1.438 pp | 0.00% +0.003 pp | USD3.86 +30.1% | 6 qtrs — |
| 12 | WOODLINE PARTNERS LP | 4.00M +1.4M (+51.6%) | 20.08M +12.0M (+149.5%) | 2.68% +0.904 pp | 0.08% +0.040 pp | USD4.06 +23.6% | 15 qtrs — |
| 13 | BALYASNY ASSET MANAGEMENT L.P. | 3.30M +2.0M (+154.3%) | 16.56M +12.6M (+318.6%) | 2.21% +1.338 pp | 0.02% +0.016 pp | USD4.25 +18.1% | 4 qtrs — |
| 14 | LONGAEVA PARTNERS L.P. | 3.10M +3.1M (+100.0%) | 15.56M +15.6M (+100.0%) | 2.08% +2.079 pp | 1.31% +1.305 pp | USD5.02 +0.0% | 1 qtrs NEW |
| 15 | MAK CAPITAL ONE LLC | 2.96M +3.0M (+100.0%) | 14.85M +14.9M (+100.0%) | 1.98% +1.984 pp | 1.63% +1.634 pp | USD5.02 +0.0% | 1 qtrs NEW |
| 16 | NUVEEN, LLC | 2.92M +2.2M (+327.1%) | 14.63M +12.6M (+603.0%) | 1.96% +1.495 pp | 0.00% +0.003 pp | USD4.46 +12.6% | 4 qtrs — |
| 17 | GEODE CAPITAL MANAGEMENT, LLC | 2.90M +466.0K (+19.1%) | 14.58M +7.1M (+96.1%) | 1.95% +0.304 pp | 0.00% +0.000 pp | USD6.62 -24.2% | 22 qtrs — |
| 18 | MORGAN STANLEY | 2.86M -173.7K (-5.7%) | 14.34M +5.1M (+55.2%) | 1.92% -0.128 pp | 0.00% +0.000 pp | USD3.68 +36.4% | 22 qtrs — |
| 19 | MILLENNIUM MANAGEMENT LLC | 2.84M +14.0K (+0.5%) | 14.24M +5.6M (+65.4%) | 1.90% -0.001 pp | 0.01% +0.002 pp | USD2.64 +90.2% | 18 qtrs — |
| 20 | OPALEYE MANAGEMENT INC. | 2.60M +— (+0.0%) | 13.05M +5.1M (+64.6%) | 1.74% -0.009 pp | 1.72% +0.601 pp | USD3.05 +64.6% | 2 qtrs — |
| 21 | PALO ALTO INVESTORS LP | 2.38M +2.4M (+100.0%) | 11.97M +12.0M (+100.0%) | 1.60% +1.599 pp | 1.67% +1.666 pp | USD5.02 +0.0% | 1 qtrs NEW |
| 22 | QUBE RESEARCH & TECHNOLOGIES LTD | 2.38M +1.8M (+315.9%) | 11.96M +10.2M (+584.5%) | 1.60% +1.211 pp | 0.01% +0.010 pp | USD4.70 +6.8% | 8 qtrs — |
| 23 | TFG ASSET MANAGEMENT GP LTD | 2.03M -80.0K (-3.8%) | 10.20M +3.8M (+58.4%) | 1.36% -0.061 pp | 2.15% +1.290 pp | USD3.53 +42.2% | 7 qtrs — |
| 24 | GOLDMAN SACHS GROUP INC | 1.77M -637.7K (-26.5%) | 8.88M +1.5M (+21.0%) | 1.19% -0.436 pp | 0.00% +0.000 pp | USD3.74 +34.2% | 21 qtrs — |
| 25 | BANK OF AMERICA CORP /DE/ | 1.61M +311.3K (+24.1%) | 8.06M +4.1M (+104.2%) | 1.08% +0.204 pp | 0.00% +0.000 pp | USD2.70 +85.9% | 22 qtrs — |
| 26 | SPHERA FUNDS MANAGEMENT LTD. | 1.32M -478.2K (-26.6%) | 6.61M +1.1M (+20.7%) | 0.88% -0.327 pp | 1.28% +0.123 pp | USD4.17 +20.4% | 5 qtrs — |
| 27 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.06M +266.8K (+33.8%) | 5.31M +2.9M (+120.2%) | 0.71% +0.176 pp | 0.00% +0.000 pp | USD5.63 -10.8% | 22 qtrs — |
| 28 | D. E. SHAW & CO., INC. | 1.05M +1.0M (+100.0%) | 5.25M +5.3M (+100.0%) | 0.70% +0.702 pp | 0.00% +0.003 pp | USD5.02 +0.0% | 1 qtrs NEW |
| 29 | J. GOLDMAN & CO LP | 993.8K -113.2K (-10.2%) | 4.99M +1.6M (+47.8%) | 0.67% -0.080 pp | 0.13% +0.047 pp | USD3.05 +64.6% | 2 qtrs — |
| 30 | INVESCO LTD. | 972.4K +770.5K (+381.5%) | 4.88M +4.3M (+692.6%) | 0.65% +0.516 pp | 0.00% +0.001 pp | USD4.60 +9.1% | 19 qtrs — |
| 31 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 903.4K -76.8K (-7.8%) | 4.54M +1.5M (+51.7%) | 0.61% -0.055 pp | 0.00% +0.001 pp | USD20.14 -75.1% | 22 qtrs — |
| 32 | ACADIAN ASSET MANAGEMENT LLC | 861.2K +328.9K (+61.8%) | 4.32M +2.7M (+166.6%) | 0.58% +0.219 pp | 0.01% +0.004 pp | USD3.72 +34.9% | 16 qtrs — |
| 33 | RENAISSANCE TECHNOLOGIES LLC | 802.6K +49.0K (+6.5%) | 4.03M +1.7M (+75.3%) | 0.54% +0.030 pp | 0.01% +0.003 pp | USD3.18 +57.9% | 17 qtrs — |
| 34 | NORTHERN TRUST CORP | 792.0K +4.3K (+0.5%) | 3.98M +1.6M (+65.5%) | 0.53% +0.000 pp | 0.00% +0.000 pp | USD6.14 -18.2% | 22 qtrs — |
| 35 | AQR CAPITAL MANAGEMENT LLC | 776.3K +202.2K (+35.2%) | 3.90M +2.1M (+122.6%) | 0.52% +0.134 pp | 0.00% +0.001 pp | USD3.38 +48.5% | 8 qtrs — |
| 36 | DIMENSIONAL FUND ADVISORS LP | 718.7K -48.3K (-6.3%) | 3.61M +1.3M (+54.2%) | 0.48% -0.035 pp | 0.00% +0.000 pp | USD5.69 -11.8% | 17 qtrs — |
| 37 | SIRIOS CAPITAL MANAGEMENT L P | 710.3K -259.9K (-26.8%) | 3.57M +606.4K (+20.5%) | 0.48% -0.178 pp | 0.44% +0.059 pp | USD2.03 +147.3% | 4 qtrs — |
| 38 | JACOBS LEVY EQUITY MANAGEMENT, INC | 683.9K +661.3K (+2,927.5%) | 3.43M +3.4M (+4,883.0%) | 0.46% +0.443 pp | 0.01% +0.013 pp | USD4.95 +1.4% | 2 qtrs — |
| 39 | RUSSELL INVESTMENTS GROUP, LTD. | 683.0K +664.8K (+3,648.7%) | 3.43M +3.4M (+6,070.1%) | 0.46% +0.446 pp | 0.00% +0.004 pp | USD4.97 +1.0% | 2 qtrs — |
| 40 | MUTUAL OF AMERICA CAPITAL MANAGEMENT LLC | 642.0K -424.9K (-39.8%) | 3.22M -31.1K (-1.0%) | 0.43% -0.289 pp | 0.03% 0.000 pp | USD4.97 +1.0% | 7 qtrs — |
| 41 | KENNEDY CAPITAL MANAGEMENT LLC | 639.9K -558.0 (-0.1%) | 3.21M +1.3M (+64.4%) | 0.43% -0.003 pp | 0.07% +0.025 pp | USD4.04 +24.3% | 10 qtrs — |
| 42 | PARKMAN HEALTHCARE PARTNERS LLC | 601.2K +195.2K (+48.1%) | 3.02M +1.8M (+143.8%) | 0.40% +0.130 pp | 0.29% +0.158 pp | USD5.56 -9.7% | 8 qtrs — |
| 43 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 583.9K +— (+0.0%) | 2.93M +1.2M (+64.6%) | 0.39% -0.002 pp | 0.04% +0.010 pp | USD30.23 -83.4% | 22 qtrs — |
| 44 | WELLS FARGO & COMPANY/MN | 573.7K +164.3K (+40.1%) | 2.88M +1.6M (+130.6%) | 0.38% +0.109 pp | 0.00% +0.000 pp | USD4.29 +17.0% | 22 qtrs — |
| 45 | DEUTSCHE BANK AG\ | 560.7K -943.6K (-62.7%) | 2.81M -1.8M (-38.6%) | 0.38% -0.638 pp | 0.00% -0.001 pp | USD3.69 +36.0% | 22 qtrs — |
| 46 | HENNION & WALSH ASSET MANAGEMENT, INC. | 535.0K +59.1K (+12.4%) | 2.69M +1.2M (+85.0%) | 0.36% +0.038 pp | 0.09% +0.040 pp | USD4.87 +3.1% | 7 qtrs — |
| 47 | SCHONFELD STRATEGIC ADVISORS LLC | 522.8K +310.6K (+146.4%) | 2.62M +2.0M (+305.5%) | 0.35% +0.208 pp | 0.01% +0.008 pp | USD4.20 +19.5% | 16 qtrs — |
| 48 | MARSHALL WACE, LLP | 521.0K +521.0K (+100.0%) | 2.62M +2.6M (+100.0%) | 0.35% +0.349 pp | 0.00% +0.002 pp | USD5.02 +0.0% | 8 qtrs — |
| 49 | JANE STREET GROUP, LLC | 513.8K +294.3K (+134.1%) | 2.58M +1.9M (+285.3%) | 0.34% +0.197 pp | 0.00% +0.000 pp | USD4.61 +8.9% | 13 qtrs — |
| 50 | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 482.6K +— (+0.0%) | 2.42M +950.6K (+64.6%) | 0.32% -0.002 pp | 0.49% +0.315 pp | USD29.57 -83.0% | 22 qtrs — |
| 51 | PRICE T ROWE ASSOCIATES INC /MD/ | 445.1K -39.7K (-8.2%) | 2.24M +756.0K (+51.1%) | 0.30% -0.028 pp | 0.00% +0.000 pp | USD6.52 -23.0% | 9 qtrs — |
| 52 | SUMMITTX CAPITAL, L.P. | 438.5K +196.5K (+81.2%) | 2.20M +1.5M (+198.2%) | 0.29% +0.131 pp | 0.07% +0.036 pp | USD3.93 +27.7% | 2 qtrs — |
| 53 | WELLINGTON MANAGEMENT GROUP LLP | 398.1K +398.1K (+100.0%) | 2.00M +2.0M (+100.0%) | 0.27% +0.267 pp | 0.00% +0.000 pp | USD5.02 +0.0% | 1 qtrs NEW |
| 54 | UBS GROUP AG | 377.1K +31.0K (+8.9%) | 1.89M +837.3K (+79.3%) | 0.25% +0.020 pp | 0.00% +0.000 pp | USD4.85 +3.5% | 17 qtrs — |
| 55 | POINT72 ASSET MANAGEMENT, L.P. | 371.2K +281.1K (+312.2%) | 1.86M +1.6M (+578.5%) | 0.25% +0.188 pp | 0.00% +0.002 pp | USD4.54 +10.6% | 8 qtrs — |
| 56 | BANK OF NEW YORK MELLON CORP | 361.7K +53.5K (+17.4%) | 1.82M +875.6K (+93.2%) | 0.24% +0.035 pp | 0.00% +0.000 pp | USD4.26 +17.8% | 22 qtrs — |
| 57 | CINCTIVE CAPITAL MANAGEMENT LP | 359.0K +293.5K (+448.4%) | 1.80M +1.6M (+802.5%) | 0.24% +0.197 pp | 0.10% +0.088 pp | USD5.08 -1.2% | 8 qtrs — |
| 58 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 356.6K +2.9K (+0.8%) | 1.79M +711.3K (+65.9%) | 0.24% +0.001 pp | 0.03% +0.011 pp | USD2.69 +86.6% | 3 qtrs — |
| 59 | DIADEMA PARTNERS LP | 350.0K +350.0K (+100.0%) | 1.76M +1.8M (+100.0%) | 0.23% +0.235 pp | 0.30% +0.303 pp | USD5.02 +0.0% | 1 qtrs NEW |
| 60 | TWO SIGMA INVESTMENTS, LP | 332.0K +52.9K (+19.0%) | 1.67M +815.5K (+95.8%) | 0.22% +0.035 pp | 0.00% +0.001 pp | USD2.97 +69.0% | 12 qtrs — |
| 61 | BARCLAYS PLC | 290.0K +112.2K (+63.1%) | 1.46M +403.2K (+38.3%) | 0.19% +0.075 pp | 0.00% +0.000 pp | USD5.13 -2.1% | 16 qtrs — |
| 62 | DAFNA CAPITAL MANAGEMENT LLC | 272.8K +272.8K (+100.0%) | 1.37M +1.4M (+100.0%) | 0.18% +0.183 pp | 0.32% +0.318 pp | USD5.02 +0.0% | 1 qtrs NEW |
| 63 | AMERICAN CENTURY COMPANIES INC | 251.2K +14.4K (+6.1%) | 1.26M +538.8K (+74.6%) | 0.17% +0.009 pp | 0.00% +0.000 pp | USD4.68 +7.3% | 12 qtrs — |
| 64 | XTX TOPCO LTD | 243.3K +95.5K (+64.6%) | 1.22M +770.5K (+170.9%) | 0.16% +0.064 pp | 0.03% +0.009 pp | USD3.82 +31.4% | 5 qtrs — |
| 65 | IKARIAN CAPITAL, LLC | 230.2K +230.2K (+100.0%) | 1.16M +1.2M (+100.0%) | 0.15% +0.154 pp | 0.09% +0.090 pp | USD5.02 +0.0% | 1 qtrs NEW |
| 66 | IEQ CAPITAL, LLC | 183.0K +32.7K (+21.7%) | 918.6K +460.1K (+100.3%) | 0.12% +0.021 pp | 0.00% +0.001 pp | USD2.71 +85.2% | 4 qtrs — |
| 67 | ADVISOR GROUP HOLDINGS, INC. | 147.4K +— (+0.0%) | 739.8K +281.1K (+61.3%) | 0.10% -0.001 pp | 0.00% +0.000 pp | USD2.70 +85.9% | 19 qtrs — |
| 68 | RAFFERTY ASSET MANAGEMENT, LLC | 141.6K +141.6K (+100.0%) | 711.1K +711.1K (+100.0%) | 0.10% +0.095 pp | 0.00% +0.003 pp | USD5.02 +0.0% | 1 qtrs NEW |
| 69 | ALLIANCEBERNSTEIN L.P. | 140.7K +— (+0.0%) | 706.5K +277.3K (+64.6%) | 0.09% -0.001 pp | 0.00% +0.000 pp | USD4.16 +20.7% | 11 qtrs — |
| 70 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 137.8K +— (+0.0%) | 691.8K +271.5K (+64.6%) | 0.09% -0.001 pp | 0.01% +0.006 pp | USD2.59 +93.8% | 3 qtrs — |
| 71 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 130.1K -2.6K (-1.9%) | 655.1K +250.4K (+61.9%) | 0.09% -0.002 pp | 0.00% +0.000 pp | USD5.60 -10.4% | 11 qtrs — |
| 72 | RHUMBLINE ADVISERS | 126.5K -6.1K (-4.6%) | 634.8K +230.4K (+57.0%) | 0.08% -0.005 pp | 0.00% +0.000 pp | USD4.67 +7.5% | 11 qtrs — |
| 73 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 123.8K +29.2K (+30.9%) | 621.2K +332.9K (+115.4%) | 0.08% +0.019 pp | 0.01% +0.006 pp | USD3.03 +65.7% | 4 qtrs — |
| 74 | JUMP FINANCIAL, LLC | 122.9K +122.9K (+100.0%) | 616.7K +616.7K (+100.0%) | 0.08% +0.082 pp | 0.01% +0.008 pp | USD5.02 +0.0% | 1 qtrs NEW |
| 75 | CAPTION MANAGEMENT, LLC | 119.5K +119.5K (+100.0%) | 599.8K +599.8K (+100.0%) | 0.08% +0.080 pp | 0.00% +0.004 pp | USD5.02 +0.0% | 1 qtrs NEW |
| 76 | DNB ASSET MANAGEMENT AS | 118.3K +33.8K (+40.0%) | 594.0K +336.2K (+130.4%) | 0.08% +0.022 pp | 0.00% +0.001 pp | USD4.37 +14.9% | 8 qtrs — |
| 77 | J. SAFRA SARASIN HOLDING AG | 117.8K -105.5K (-47.2%) | 591.2K -89.6K (-13.2%) | 0.08% -0.072 pp | 0.01% -0.001 pp | USD3.39 +48.1% | 5 qtrs — |
| 78 | PERSISTENT ASSET PARTNERS LTD | 93.7K +93.7K (+100.0%) | 470.2K +470.2K (+100.0%) | 0.06% +0.063 pp | 0.21% +0.211 pp | USD5.02 +0.0% | 1 qtrs NEW |
| 79 | QUARRY LP | 75.0K -35.0K (-31.8%) | 376.5K +41.0K (+12.2%) | 0.05% -0.024 pp | 0.06% -0.015 pp | USD3.37 +49.0% | 8 qtrs — |
| 80 | CITADEL ADVISORS LLC | 70.4K +9.2K (+15.0%) | 353.4K +166.7K (+89.3%) | 0.05% +0.006 pp | 0.00% +0.000 pp | USD3.31 +51.7% | 15 qtrs — |
| 81 | BOOTHBAY FUND MANAGEMENT, LLC | 64.1K +64.1K (+100.0%) | 321.6K +321.6K (+100.0%) | 0.04% +0.043 pp | 0.00% +0.005 pp | USD5.02 +0.0% | 1 qtrs NEW |
| 82 | BNP PARIBAS ARBITRAGE, SNC | 61.6K +41.8K (+211.9%) | 309.1K +248.9K (+413.4%) | 0.04% +0.028 pp | 0.00% +0.000 pp | USD4.54 +10.6% | 5 qtrs — |
| 83 | SEI INVESTMENTS CO | 58.3K +58.3K (+100.0%) | 292.5K +292.5K (+100.0%) | 0.04% +0.039 pp | 0.00% +0.000 pp | USD5.02 +0.0% | 1 qtrs NEW |
| 84 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 54.8K +9.8K (+21.8%) | 275.1K +137.9K (+100.5%) | 0.04% +0.006 pp | 0.00% +0.000 pp | USD5.33 -5.8% | 7 qtrs — |
| 85 | JPMORGAN CHASE & CO | 53.7K +6.8K (+14.6%) | 269.7K +126.7K (+88.6%) | 0.04% +0.004 pp | 0.00% +0.000 pp | USD5.79 -13.3% | 22 qtrs — |
| 86 | VIRTUS INVESTMENT ADVISERS, INC. | 53.5K +11.5K (+27.5%) | 268.7K +140.6K (+109.8%) | 0.04% +0.008 pp | 0.07% +0.036 pp | USD2.75 +82.5% | 4 qtrs — |
| 87 | WINTON GROUP LTD | 53.4K +53.4K (+100.0%) | 268.1K +268.1K (+100.0%) | 0.04% +0.036 pp | 0.01% +0.009 pp | USD5.02 +0.0% | 1 qtrs NEW |
| 88 | PROFUND ADVISORS LLC | 53.0K +53.0K (+100.0%) | 266.1K +266.1K (+100.0%) | 0.04% +0.036 pp | 0.01% +0.008 pp | USD5.02 +0.0% | 1 qtrs NEW |
| 89 | QUADRATURE CAPITAL LTD | 48.6K +48.6K (+100.0%) | 243.8K +243.8K (+100.0%) | 0.03% +0.033 pp | 0.00% +0.003 pp | USD5.02 +0.0% | 4 qtrs — |
| 90 | ADAR1 CAPITAL MANAGEMENT, LLC | 48.0K +48.0K (+100.0%) | 241.0K +241.0K (+100.0%) | 0.03% +0.032 pp | 0.02% +0.018 pp | USD5.02 +0.0% | 1 qtrs NEW |
| 91 | TD ASSET MANAGEMENT INC | 46.8K +— (+0.0%) | 235.2K +92.3K (+64.6%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD6.63 -24.3% | 8 qtrs — |
| 92 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 44.8K +28.7K (+178.3%) | 224.9K +175.8K (+358.0%) | 0.03% +0.019 pp | 0.00% +0.000 pp | USD5.12 -2.0% | 16 qtrs — |
| 93 | ALLEGHENY FINANCIAL GROUP LTD | 42.9K +— (+0.0%) | 215.4K +84.5K (+64.6%) | 0.03% 0.000 pp | 0.03% +0.007 pp | USD2.60 +93.1% | 10 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 88 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.76% | 436.3K | 0.65% |
| 2 | Global X - S&P Biotech ETF CURE.AX | 0.34% | 120.7K | 0.45% |
| 3 | State Street SPDR S&P Biotech ETF XBI | 0.33% | 36.25M | 0.35% |
| 4 | Fidelity Disruptive Medicine ETF FMED | 0.29% | 135.1K | 0.50% |
| 5 | iShares Micro-Cap ETF IWC | 0.20% | 3.01M | 0.60% |
| 6 | Vanguard U.S. Momentum Factor ETF VFMO | 0.15% | 2.55M | 0.13% |
| 7 | Invesco Russell 2000 Dynamic Multifactor ETF OMFS | 0.08% | 217.5K | 0.39% |
| 8 | Fidelity Enhanced Small Cap ETF FESM | 0.07% | 3.99M | 0.28% |
| 9 | Pacer WealthShield ETF PWS | 0.07% | 16.8K | 0.60% |
| 10 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.07% | 302.3K | 0.40% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.20
Neutral
Ratio by volume
3.00
Bullish
Buys
12
Sells
10
Shares acquired
2.79M
Shares disposed
59.7K
Cash buys
1.00
Cash sales
10.00
Net activity
+2,729,553
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-10 | Carson William H. | Director | P-Purchase | A | Common Stock | 8,000 | 6.20 | 49.6K | 70,405 | D | ↗ |
| 2026-03-10 | Carson William H. | Director | P-Purchase | A | Common Stock | 8,000 | 5.67 | 45.4K | 62,405 | D | ↗ |
| 2026-03-02 | Yednock Ted | Officer | S-Sale | D | Common Stock | 5,566 | 5.42 | 30.2K | 154,161 | D | ↗ |
| 2026-03-02 | Overdorf Michael | Officer | S-Sale | D | Common Stock | 4,339 | 5.42 | 23.5K | 182,625 | D | ↗ |
| 2026-03-02 | Lew Jennifer | Officer | S-Sale | D | Common Stock | 5,565 | 5.42 | 30.2K | 170,700 | D | ↗ |
| 2026-03-02 | Dananberg Jamie | Officer | S-Sale | D | Common Stock | 5,820 | 5.43 | 31.6K | 123,582 | D | ↗ |
| 2026-03-02 | ARTIS DEAN RICHARD | Officer | S-Sale | D | Common Stock | 5,894 | 5.43 | 32.0K | 180,093 | D | ↗ |
| 2026-02-19 | Yednock Ted | Officer | A-Award | A | Common Stock | 62,500 | 0.00 | — | 159,727 | D | ↗ |
| 2026-02-19 | Overdorf Michael | Officer | A-Award | A | Common Stock | 62,500 | 0.00 | — | 186,964 | D | ↗ |
| 2026-02-19 | Love Douglas | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,250,000 | 5.10 | 6.38M | 1,250,000 | D | ↗ |
| 2026-02-19 | Lew Jennifer | Officer | A-Award | A | Common Stock | 62,500 | 0.00 | — | 176,265 | D | ↗ |
| 2026-02-19 | Dananberg Jamie | Officer | A-Award | A | Common Stock | 56,250 | 0.00 | — | 129,402 | D | ↗ |
| 2026-02-19 | ARTIS DEAN RICHARD | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 5.10 | 1.28M | 250,000 | D | ↗ |
| 2026-02-18 | Yednock Ted | Officer | S-Sale | D | Common Stock | 7,857 | 5.11 | 40.1K | 97,227 | D | ↗ |
| 2026-02-18 | Overdorf Michael | Officer | S-Sale | D | Common Stock | 6,225 | 5.10 | 31.7K | 124,464 | D | ↗ |
| 2026-02-18 | Lew Jennifer | Officer | S-Sale | D | Common Stock | 7,851 | 5.11 | 40.1K | 113,765 | D | ↗ |
| 2026-02-18 | Dananberg Jamie | Officer | S-Sale | D | Common Stock | 5,290 | 5.10 | 27.0K | 73,152 | D | ↗ |
| 2026-02-18 | ARTIS DEAN RICHARD | Officer | S-Sale | D | Common Stock | 5,290 | 5.10 | 27.0K | 123,487 | D | ↗ |
| 2025-12-30 | Carson William H. | Director | P-Purchase | A | Common Stock | 4,115 | 5.02 | 20.7K | 54,405 | D | ↗ |
| 2025-12-01 | Choi Jung | Director | P-Purchase | A | Common Stock | 33,000 | 4.19 | 138.3K | 33,000 | I | ↗ |
| 2025-12-01 | Carson William H. | Director | P-Purchase | A | Common Stock | 4,115 | 4.47 | 18.4K | 50,290 | D | ↗ |
| 2025-11-21 | Satter Muneer A | Director | P-Purchase | A | Common Stock | 422,613 | 4.28 | 1.81M | 9,728,637 | I | ↗ |
| 2025-11-20 | Satter Muneer A | Director | P-Purchase | A | Common Stock | 400,000 | 4.48 | 1.79M | 9,306,024 | I | ↗ |
| 2025-11-19 | Satter Muneer A | Director | P-Purchase | A | Common Stock | 500,000 | 3.94 | 1.97M | 8,906,024 | I | ↗ |
| 2025-11-18 | Satter Muneer A | Director | P-Purchase | A | Common Stock | 500,000 | 3.18 | 1.59M | 8,406,024 | I | ↗ |
| 2025-11-17 | Satter Muneer A | Director | P-Purchase | A | Common Stock | 500,000 | 2.99 | 1.50M | 7,906,024 | I | ↗ |
| 2025-10-30 | Carson William H. | Director | P-Purchase | A | Common Stock | 4,115 | 3.17 | 13.0K | 46,175 | D | ↗ |
| 2025-09-30 | Carson William H. | Director | P-Purchase | A | Common Stock | 4,115 | 3.05 | 12.6K | 42,060 | D | ↗ |
| 2025-09-02 | Carson William H. | Director | P-Purchase | A | Common Stock | 4,115 | 2.09 | 8.6K | 37,945 | D | ↗ |
| 2025-07-30 | Carson William H. | Director | P-Purchase | A | Common Stock | 4,115 | 2.43 | 10.0K | 33,830 | D | ↗ |
| 2025-07-14 | Yednock Ted | Officer | S-Sale | D | Common Stock | 1,116 | 2.58 | 2.9K | 105,084 | D | ↗ |
| 2025-07-14 | Overdorf Michael | Officer | S-Sale | D | Common Stock | 853 | 2.61 | 2.2K | 130,689 | D | ↗ |
| 2025-07-14 | Lew Jennifer | Officer | S-Sale | D | Common Stock | 1,117 | 2.58 | 2.9K | 121,616 | D | ↗ |
| 2025-06-30 | Carson William H. | Director | P-Purchase | A | Common Stock | 4,115 | 2.46 | 10.1K | 29,715 | D | ↗ |
| 2025-06-05 | Waddill William D. | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 2.55 | 140.3K | 55,000 | D | ↗ |
| 2025-06-05 | WIGGANS THOMAS G | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 2.55 | 140.3K | 55,000 | D | ↗ |
| 2025-06-05 | Satter Muneer A | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 55,000 | 2.55 | 140.3K | 55,000 | D | ↗ |
| 2025-06-05 | JONES WILLIAM A JR | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 2.55 | 140.3K | 55,000 | D | ↗ |
| 2025-06-05 | Cockroft Bettina M. | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 2.55 | 140.3K | 55,000 | D | ↗ |
| 2025-06-05 | Choi Jung | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 2.55 | 140.3K | 55,000 | D | ↗ |
| 2025-06-05 | Carson William H. | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 2.55 | 140.3K | 55,000 | D | ↗ |
| 2025-02-27 | Yednock Ted | Officer | A-Award | A | Stock Option (Right to Buy) | 272,575 | 2.50 | 681.4K | 272,575 | D | ↗ |
| 2025-02-27 | Overdorf Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 272,575 | 2.50 | 681.4K | 272,575 | D | ↗ |
| 2025-02-27 | Love Douglas | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,300,000 | 2.50 | 3.25M | 1,300,000 | D | ↗ |
| 2025-02-27 | Lew Jennifer | Officer | A-Award | A | Stock Option (Right to Buy) | 272,575 | 2.50 | 681.4K | 272,575 | D | ↗ |
| 2025-02-27 | Dananberg Jamie | Officer | A-Award | A | Stock Option (Right to Buy) | 228,225 | 2.50 | 570.6K | 228,225 | D | ↗ |
| 2025-02-27 | ARTIS DEAN RICHARD | Officer | A-Award | A | Stock Option (Right to Buy) | 272,575 | 2.50 | 681.4K | 272,575 | D | ↗ |
| 2025-02-18 | Yednock Ted | Officer | S-Sale | D | Common Stock | 8,345 | 2.91 | 24.3K | 61,237 | D | ↗ |
| 2025-02-18 | Overdorf Michael | Officer | S-Sale | D | Common Stock | 6,618 | 2.95 | 19.5K | 86,579 | D | ↗ |
| 2025-02-18 | Lew Jennifer | Officer | S-Sale | D | Common Stock | 6,912 | 2.92 | 20.2K | 77,770 | D | ↗ |
| 2025-02-18 | Dananberg Jamie | Officer | S-Sale | D | Common Stock | 5,521 | 2.96 | 16.3K | 33,479 | D | ↗ |
| 2025-02-18 | ARTIS DEAN RICHARD | Officer | S-Sale | D | Common Stock | 5,515 | 2.97 | 16.4K | 83,814 | D | ↗ |
| 2025-02-13 | Yednock Ted | Officer | S-Sale | D | Common Stock | 1,783 | 2.99 | 5.3K | 69,582 | D | ↗ |
| 2025-02-13 | Overdorf Michael | Officer | S-Sale | D | Common Stock | 1,425 | 2.99 | 4.3K | 93,197 | D | ↗ |
| 2025-02-13 | Love Douglas | Director / Officer | S-Sale | D | Common Stock | 5,021 | 2.95 | 14.8K | 351,554 | D | ↗ |
| 2025-02-13 | Lew Jennifer | Officer | S-Sale | D | Common Stock | 1,786 | 2.98 | 5.3K | 84,682 | D | ↗ |
| 2025-01-09 | JONES WILLIAM A JR | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-01-06 | Love Douglas | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 37,994 | 1.41 | 53.6K | 0 | D | ↗ |
| 2024-12-02 | Carson William H. | Director | P-Purchase | A | Common Stock | 3,200 | 5.33 | 17.1K | 25,600 | D | ↗ |
| 2024-10-30 | Love Douglas | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 36,050 | 1.85 | 66.7K | 0 | D | ↗ |
| 2024-10-15 | Yednock Ted | Officer | S-Sale | D | Common Stock | 5,408 | 7.41 | 40.1K | 71,365 | D | ↗ |
| 2024-10-01 | Carson William H. | Director | P-Purchase | A | Common Stock | 3,200 | 5.97 | 19.1K | 22,400 | D | ↗ |
| 2024-09-19 | Yednock Ted | Officer | S-Sale | D | Common Stock | 4,500 | 7.10 | 32.0K | 0 | I | ↗ |
| 2024-09-12 | Yednock Ted | Officer | S-Sale | D | Common Stock | 5,500 | 6.16 | 33.9K | 4,500 | — | ↗ |
| 2024-09-05 | Yednock Ted | Officer | S-Sale | D | Common Stock | 5,500 | 5.64 | 31.0K | 10,000 | — | ↗ |
| 2024-09-03 | Carson William H. | Director | P-Purchase | A | Common Stock | 3,200 | 5.48 | 17.5K | 19,200 | — | ↗ |
| 2024-08-29 | Yednock Ted | Officer | S-Sale | D | Common Stock | 5,500 | 5.95 | 32.7K | 15,500 | — | ↗ |
| 2024-08-01 | Carson William H. | Director | P-Purchase | A | Common Stock | 3,200 | 6.24 | 20.0K | 16,000 | — | ↗ |
| 2024-07-15 | Yednock Ted | Officer | S-Sale | D | Common Stock | 1,106 | 6.02 | 6.7K | 71,365 | — | ↗ |
| 2024-07-15 | Overdorf Michael | Officer | S-Sale | D | Common Stock | 784 | 6.02 | 4.7K | 94,622 | — | ↗ |
| 2024-07-15 | Lew Jennifer | Officer | S-Sale | D | Common Stock | 1,104 | 6.03 | 6.7K | 86,468 | — | ↗ |
| 2024-07-01 | Carson William H. | Director | P-Purchase | A | Common Stock | 3,200 | 5.00 | 16.0K | 12,800 | — | ↗ |
| 2024-06-05 | Waddill William D. | Director | A-Award | A | Stock Option (Right to Buy) | 44,000 | 6.79 | 298.8K | 44,000 | — | ↗ |
| 2024-06-05 | WIGGANS THOMAS G | Director | A-Award | A | Stock Option (Right to Buy) | 44,000 | 6.79 | 298.8K | 44,000 | — | ↗ |
| 2024-06-05 | Satter Muneer A | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 44,000 | 6.79 | 298.8K | 44,000 | — | ↗ |
| 2024-06-05 | Cockroft Bettina M. | Director | A-Award | A | Stock Option (Right to Buy) | 44,000 | 6.79 | 298.8K | 44,000 | — | ↗ |
| 2024-06-05 | Choi Jung | Director | A-Award | A | Stock Option (Right to Buy) | 44,000 | 6.79 | 298.8K | 44,000 | — | ↗ |
| 2024-06-05 | Carson William H. | Director | A-Award | A | Stock Option (Right to Buy) | 44,000 | 6.79 | 298.8K | 44,000 | — | ↗ |
| 2024-06-03 | Carson William H. | Director | P-Purchase | A | Common Stock | 3,200 | 4.83 | 15.5K | 9,600 | — | ↗ |
| 2024-05-01 | Carson William H. | Director | P-Purchase | A | Common Stock | 3,200 | 4.68 | 15.0K | 6,400 | — | ↗ |
| 2024-04-08 | Carson William H. | Director | P-Purchase | A | Common Stock | 3,200 | 6.07 | 19.4K | 3,200 | — | ↗ |
| 2024-02-27 | Yednock Ted | Officer | A-Award | A | Common Stock | 44,963 | 0.00 | — | 106,200 | D | ↗ |
| 2024-02-27 | Overdorf Michael | Officer | A-Award | A | Common Stock | 44,963 | 0.00 | — | 131,542 | D | ↗ |
| 2024-02-27 | Lew Jennifer | Officer | A-Award | A | Common Stock | 44,963 | 0.00 | — | 122,733 | D | ↗ |
| 2024-02-27 | Dananberg Jamie | Officer | A-Award | A | Common Stock | 44,963 | 0.00 | — | 78,442 | D | ↗ |
| 2024-02-27 | ARTIS DEAN RICHARD | Officer | A-Award | A | Common Stock | 44,963 | 0.00 | — | 128,777 | D | ↗ |
| 2024-02-20 | Yednock Ted | Officer | S-Sale | D | Common Stock | 2,604 | 5.51 | 14.3K | 72,471 | — | ↗ |
| 2024-02-20 | Overdorf Michael | Officer | S-Sale | D | Common Stock | 1,951 | 5.48 | 10.7K | 85,641 | — | ↗ |
| 2024-02-20 | Lew Jennifer | Officer | S-Sale | D | Common Stock | 2,593 | 5.53 | 14.3K | 82,058 | — | ↗ |
| 2024-02-16 | Yednock Ted | Officer | A-Award | A | Common Stock | 39,000 | 0.00 | — | 75,075 | — | ↗ |
| 2024-02-16 | Overdorf Michael | Officer | A-Award | A | Common Stock | 39,000 | 0.00 | — | 87,592 | — | ↗ |
| 2024-02-16 | Love Douglas | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 656,200 | 5.13 | 3.37M | 656,200 | — | ↗ |
| 2024-02-16 | Lew Jennifer | Officer | A-Award | A | Stock Option (Right to Buy) | 160,000 | 5.13 | 820.8K | 160,000 | — | ↗ |
| 2024-02-16 | Dananberg Jamie | Officer | A-Award | A | Common Stock | 39,000 | 0.00 | — | 39,000 | — | ↗ |
| 2024-02-16 | ARTIS DEAN RICHARD | Officer | A-Award | A | Common Stock | 39,000 | 0.00 | — | 89,329 | — | ↗ |
| 2024-02-12 | Yednock Ted | Officer | S-Sale | D | Common Stock | 1,810 | 5.54 | 10.0K | 36,075 | — | ↗ |
| 2024-02-12 | Overdorf Michael | Officer | S-Sale | D | Common Stock | 1,349 | 5.53 | 7.5K | 48,592 | — | ↗ |
| 2024-02-12 | Love Douglas | Director / Officer | S-Sale | D | Common Stock | 5,782 | 5.54 | 32.0K | 196,121 | — | ↗ |
| 2024-02-12 | Lew Jennifer | Officer | S-Sale | D | Common Stock | 1,809 | 5.54 | 10.0K | 45,651 | — | ↗ |
| 2023-12-27 | Yednock Ted | Officer | M-Exempt | A | Common Stock | 10,615 | 1.41 | 15.0K | 10,615 | — | ↗ |
| 2023-12-26 | Satter Muneer A | Director / 10% Owner | P-Purchase | A | Common Stock | 350,000 | 2.88 | 1.01M | 7,406,024 | — | ↗ |
| 2023-08-01 | Dananberg Jamie | Officer | A-Award | A | Stock Option (Right to Buy) | 275,000 | 3.54 | 973.5K | 275,000 | — | ↗ |
| 2023-07-27 | Dananberg Jamie | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-07-11 | Yednock Ted | Officer | S-Sale | D | Common Stock | 1,057 | 3.84 | 4.1K | 37,885 | — | ↗ |
| 2023-07-11 | Overdorf Michael | Officer | S-Sale | D | Common Stock | 978 | 3.84 | 3.8K | 45,802 | — | ↗ |
| 2023-07-11 | Lew Jennifer | Officer | S-Sale | D | Common Stock | 1,057 | 3.84 | 4.1K | 47,460 | — | ↗ |
| 2023-06-08 | Waddill William D. | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 2.88 | 69.1K | 24,000 | — | ↗ |
| 2023-06-08 | WIGGANS THOMAS G | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 2.88 | 69.1K | 24,000 | — | ↗ |
| 2023-06-08 | Satter Muneer A | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 24,000 | 2.88 | 69.1K | 24,000 | — | ↗ |
| 2023-06-08 | Cockroft Bettina M. | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 2.88 | 69.1K | 24,000 | — | ↗ |
| 2023-06-08 | Choi Jung | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 2.88 | 69.1K | 24,000 | — | ↗ |
| 2023-06-08 | Carson William H. | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 2.88 | 69.1K | 24,000 | — | ↗ |
| 2023-05-25 | Bain Capital Life Sciences Investors, LLC | 10% Owner | P-Purchase | A | Common Stock | 300,000 | 2.13 | 639.7K | 5,701,926 | — | ↗ |
| 2023-03-16 | Yednock Ted | Officer | — | D | Stock Option (Right to Buy) | 46,439 | 1.85 | 85.9K | 0 | — | ↗ |
| 2023-02-16 | Overdorf Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 77,050 | 5.94 | 457.7K | 77,050 | — | ↗ |
| 2023-02-16 | Love Douglas | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 345,000 | 5.94 | 2.05M | 345,000 | — | ↗ |
| 2023-02-16 | Lew Jennifer | Officer | A-Award | A | Common Stock | 18,975 | 0.00 | — | 48,517 | — | ↗ |
| 2023-02-15 | Love Douglas | Director / Officer | S-Sale | D | Common Stock | 6,571 | 5.87 | 38.6K | 197,646 | — | ↗ |
| 2023-02-14 | Overdorf Michael | Officer | S-Sale | D | Common Stock | 144 | 6.30 | 907.10 | 27,805 | — | ↗ |
| 2023-02-14 | Lew Jennifer | Officer | S-Sale | D | Common Stock | 166 | 6.30 | 1.0K | 29,542 | — | ↗ |
| 2023-02-13 | Overdorf Michael | Officer | S-Sale | D | Common Stock | 1,501 | 6.30 | 9.5K | 27,949 | — | ↗ |
| 2023-02-13 | Lew Jennifer | Officer | S-Sale | D | Common Stock | 1,742 | 6.31 | 11.0K | 29,708 | — | ↗ |
| 2023-02-10 | Satter Muneer A | Director / 10% Owner | P-Purchase | A | Common Stock | 2,647,058 | 6.80 | 18.00M | 7,056,024 | — | ↗ |
| 2023-01-15 | ARTIS DEAN RICHARD | Officer | A-Award | A | Stock Option (Right to Buy) | 210,000 | 0.00 | — | 210,000 | — | ↗ |
| 2023-01-06 | ARTIS DEAN RICHARD | Officer | — | D | Common Stock | 0 | 0.00 | — | 50,329 | — | ↗ |
| 2022-07-11 | Overdorf Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2022-07-11 | Mattheakis Larry | Officer | A-Award | A | Common Stock | 4,688 | 0.00 | — | 17,188 | D | ↗ |
| 2022-07-11 | Love Douglas | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 3.91 | 1.17M | 300,000 | D | ↗ |
| 2022-07-11 | Lew Jennifer | Officer | A-Award | A | Common Stock | 9,375 | 0.00 | — | 23,875 | — | ↗ |
| 2022-07-11 | Bain Capital Life Sciences Investors, LLC | 10% Owner | — | I | Pre-Funded Warrant (right to buy) | 2,739,475 | 0.00 | 2.7K | 0 | — | ↗ |
| 2022-07-07 | Satter Muneer A | Director | P-Purchase | A | Warrants (Right to Buy) | 613,497 | 0.13 | 76.7K | 613,497 | — | ↗ |
| 2022-06-09 | Waddill William D. | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 3.84 | 92.2K | 24,000 | — | ↗ |
| 2022-06-09 | WIGGANS THOMAS G | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 0.00 | — | 24,000 | — | ↗ |
| 2022-06-09 | Satter Muneer A | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 0.00 | — | 24,000 | — | ↗ |
| 2022-06-09 | Cockroft Bettina M. | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 0.00 | — | 24,000 | — | ↗ |
| 2022-06-09 | Choi Jung | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 3.84 | 92.2K | 24,000 | — | ↗ |
| 2022-06-09 | Carson William H. | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 3.84 | 92.2K | 24,000 | — | ↗ |
| 2022-04-14 | Love Douglas | Officer | P-Purchase | A | Common Stock | 60,000 | 2.45 | 146.8K | 200,942 | — | ↗ |
| 2022-02-11 | Overdorf Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 6.94 | 694.0K | 100,000 | — | ↗ |
| 2022-02-11 | Mattheakis Larry | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 6.94 | 694.0K | 100,000 | — | ↗ |
| 2022-02-11 | Love Douglas | Director / Officer | A-Award | A | Common Stock | 40,000 | 0.00 | — | 140,942 | — | ↗ |
| 2022-02-11 | Lew Jennifer | Officer | A-Award | A | Common Stock | 12,500 | 0.00 | — | 14,500 | — | ↗ |
| 2022-02-11 | Keswani Sanjay | Officer | A-Award | A | Common Stock | 12,500 | 0.00 | — | 12,500 | — | ↗ |
| 2022-01-19 | Cockroft Bettina M. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-11 | Love Douglas | Director / Officer | M-Exempt | A | Common Stock | 70,942 | 1.41 | 100.0K | 70,942 | — | ↗ |
| 2021-09-30 | Mattheakis Larry | Officer | A-Award | A | Stock Option (Right to Buy) | 220,000 | 18.61 | 4.09M | 220,000 | — | ↗ |
| 2021-09-16 | Love Douglas | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 7,500 | 1.41 | 10.6K | 37,994 | — | ↗ |
| 2021-09-13 | Yednock Ted | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,190 | 5.11 | 6.1K | 67,939 | — | ↗ |
| 2021-09-13 | Lew Jennifer | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,500 | 7.49 | 26.2K | 143,793 | — | ↗ |
| 2021-08-12 | Waddill William D. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-08 | Love Douglas | Director / Officer | M-Exempt | A | Common Stock | 3,750 | 1.41 | 5.3K | 3,750 | — | ↗ |
| 2021-06-07 | Love Douglas | Director / Officer | S-Sale | D | Common Stock | 3,750 | 22.31 | 83.7K | 0 | — | ↗ |
| 2021-06-03 | Yednock Ted | Officer | M-Exempt | D | Stock Option (Right to Buy) | 15,000 | 1.41 | 21.1K | 25,615 | — | ↗ |
| 2021-06-02 | WIGGANS THOMAS G | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 21.03 | 210.3K | 10,000 | — | ↗ |
| 2021-06-02 | Sun Ricky | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 21.03 | 210.3K | 10,000 | — | ↗ |
| 2021-06-02 | Satter Muneer A | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 21.03 | 210.3K | 10,000 | — | ↗ |
| 2021-06-02 | Choi Jung | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 21.03 | 210.3K | 10,000 | — | ↗ |
| 2021-06-02 | Carson William H. | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 21.03 | 210.3K | 10,000 | — | ↗ |
| 2021-05-27 | Lew Jennifer | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,500 | 7.49 | 26.2K | 147,293 | — | ↗ |
| 2021-04-01 | Love Douglas | Director / Officer | S-Sale | D | Common Stock | 200 | 28.19 | 5.6K | 300 | — | ↗ |
| 2021-03-31 | Love Douglas | Director / Officer | S-Sale | D | Common Stock | 7,102 | 28.11 | 199.6K | 0 | — | ↗ |
| 2021-03-30 | Love Douglas | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,750 | 1.41 | 5.3K | 60,596 | — | ↗ |
| 2021-03-29 | Love Douglas | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,750 | 1.41 | 5.3K | 64,346 | — | ↗ |
| 2021-03-25 | Yednock Ted | Officer | M-Exempt | A | Common Stock | 15,000 | 1.41 | 21.1K | 15,000 | — | ↗ |
| 2021-03-24 | Keswani Sanjay | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,995 | 7.49 | 29.9K | 182,956 | — | ↗ |
| 2021-03-23 | Lew Jennifer | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 7.49 | 37.4K | 150,793 | — | ↗ |
| 2021-02-25 | Yednock Ted | Officer | A-Award | A | Stock Option (Right to Buy) | 115,000 | 30.07 | 3.46M | 115,000 | — | ↗ |
| 2021-02-25 | Overdorf Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 115,000 | 30.07 | 3.46M | 115,000 | — | ↗ |
| 2021-02-25 | Love Douglas | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 325,000 | 30.07 | 9.77M | 325,000 | — | ↗ |
| 2021-02-25 | Lew Jennifer | Officer | A-Award | A | Stock Option (Right to Buy) | 115,000 | 30.07 | 3.46M | 115,000 | — | ↗ |
| 2021-02-25 | Keswani Sanjay | Officer | A-Award | A | Stock Option (Right to Buy) | 115,000 | 30.07 | 3.46M | 115,000 | — | ↗ |
| 2021-02-05 | Carson William H. | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 24.34 | 486.8K | 20,000 | — | ↗ |
| 2020-07-28 | Satter Muneer A | Director | C-Conversion | D | Series B Preferred Stock | 4,016,573 | 0.00 | — | 0 | — | ↗ |
| 2020-07-28 | Redmile Group, LLC | 10% Owner | C-Conversion | D | Series D Redeemable Convertible Preferred Stock | 14,062,719 | 0.00 | — | 0 | — | ↗ |
| 2020-07-28 | Lew Jennifer | Officer | P-Purchase | A | Common Stock | 2,000 | 17.00 | 34.0K | 2,000 | — | ↗ |
| 2020-07-28 | Flynn James E | 10% Owner | P-Purchase | A | Common Stock | 350,000 | 17.00 | 5.95M | 808,914 | — | ↗ |
| 2020-07-28 | Clarus Lifesciences III, L.P. | 10% Owner | C-Conversion | A | Common Stock | 643,208 | 0.00 | — | 643,208 | — | ↗ |
| 2020-07-28 | Bain Capital Life Sciences Investors, LLC | 10% Owner | C-Conversion | D | Series C Preferred Stock | 22,222,221 | 0.00 | — | 0 | — | ↗ |
| 2020-07-23 | Yednock Ted | Officer | — | D | Stock Option (Right to Buy) | 192,962 | 13.31 | 2.57M | 0 | — | ↗ |
| 2020-07-23 | YOUNG WILLIAM | Director | — | D | Stock Option (Right to Buy) | 9,080 | 13.31 | 120.9K | 0 | — | ↗ |
| 2020-07-23 | WIGGANS THOMAS G | Director | — | D | Stock Option (Right to Buy) | 9,080 | 13.31 | 120.9K | 0 | — | ↗ |
| 2020-07-23 | Sun Ricky | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-07-23 | Sonsini Peter W. | 10% Owner | — | I | Series D Preferred Stock | 231,452 | 0.00 | — | 0 | — | ↗ |
| 2020-07-23 | Satter Muneer A | Director | — | I | Series C Preferred Stock | 5,537,036 | 0.00 | — | 0 | — | ↗ |
| 2020-07-23 | SANDELL SCOTT D | 10% Owner | — | I | Series D Preferred Stock | 231,452 | 0.00 | — | 0 | — | ↗ |
| 2020-07-23 | Redmile Group, LLC | 10% Owner | — | I | Series D Redeemable Convertible Preferred Stock | 1,596,222 | 0.00 | — | 0 | — | ↗ |
| 2020-07-23 | Overdorf Michael | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-07-23 | New Enterprise Associates 15, L.P. | 10% Owner | — | D | Series C Preferred Stock | 672,636 | 0.00 | — | 0 | — | ↗ |
| 2020-07-23 | Makhzoumi Mohamad | 10% Owner | — | I | Series B Preferred Stock | 1,591,599 | 0.00 | — | 0 | — | ↗ |
| 2020-07-23 | MAKOWER JOSHUA | 10% Owner | — | I | Series B Preferred Stock | 1,591,599 | 0.00 | — | 0 | — | ↗ |
| 2020-07-23 | Love Douglas | Director / Officer | — | D | Stock Option (Right to Buy) | 36,050 | 1.86 | 67.1K | 0 | — | ↗ |
| 2020-07-23 | Lew Jennifer | Officer | — | D | Stock Option (Right to Buy) | 155,793 | 7.49 | 1.17M | 0 | — | ↗ |
| 2020-07-23 | Keswani Sanjay | Officer | — | D | Stock Option (Right to Buy) | 68,104 | 13.31 | 906.5K | 0 | — | ↗ |
| 2020-07-23 | Gallagher Carol Giltner | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-07-23 | Flynn James E | 10% Owner | — | I | Series D Preferred Stock | 458,914 | 0.00 | — | 0 | — | ↗ |
| 2020-07-23 | Florence Anthony A. Jr. | 10% Owner | — | I | Series B Preferred Stock | 1,591,599 | 0.00 | — | 0 | — | ↗ |
| 2020-07-23 | Cunningham Emmett | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-07-23 | Clarus Lifesciences III, L.P. | 10% Owner | — | I | Series B Redeemable Convertible Preferred Stock | 8,370,685 | 0.00 | — | 0 | — | ↗ |
| 2020-07-23 | Choi Jung | Director | — | D | Stock Option (Right to Buy) | 36,322 | 13.31 | 483.4K | 0 | — | ↗ |
| 2020-07-23 | Bain Capital Life Sciences Investors, LLC | 10% Owner | — | I | Series D Preferred Stock | 2,812,543 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
119.60M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Douglas Love, Esq. President & Chief Executive Officer | 670.8K | — | — | 2.52M | 371.3K | 14.9K | 3.58M | 70.47% | ↗ |
| 2 | 2025 | Ted Yednock, Ph.D. Executive Vice President and Chief Innovation Officer | 497.6K | — | 112.4K | 528.9K | 200.3K | 39.9K | 1.38M | 46.50% | ↗ |
| 3 | 2025 | Jennifer Lew. Executive Vice President and Chief Financial Officer | 495.8K | — | 112.4K | 528.9K | 200.2K | 4.0K | 1.34M | 47.81% | ↗ |
| 4 | 2024 | Douglas Love, Esq. President & Chief Executive Officer | 641.1K | — | — | 2.66M | 357.5K | 12.2K | 3.67M | 72.48% | ↗ |
| 5 | 2024 | Douglas Love, Esq. President Chief Executive Officer | 641.1K | — | — | 2.66M | 357.5K | 12.2K | 3.67M | 72.48% | ↗ |
| 6 | 2024 | Jamie Dananberg, M.D. Executive Vice President and Chief Medical Officer | 514.6K | — | 200.1K | 649.1K | 196.7K | 4.0K | 1.56M | 54.28% | ↗ |
| 7 | 2024 | Ted Yednock, Ph.D. Executive Vice President and Chief Innovation Officer | 478.8K | — | 200.1K | 649.1K | 192.6K | 43.3K | 1.56M | 54.30% | ↗ |
| 8 | 2023 | Douglas Love, Esq. President Chief Executive Officer | 593.4K | — | — | 1.47M | 375.7K | 11.0K | 2.45M | 60.05% | ↗ |
| 9 | 2023 | Rick Artis, Ph.D. Executive Vice President and Chief Scientific Officer | 442.5K | 150.0K | — | 1.03M | 200.9K | 4.0K | 1.83M | 56.41% | ↗ |
| 10 | 2023 | Ted Yednock, Ph.D. Executive Vice President and Chief Innovation Officer | 462.6K | — | 112.7K | 329.0K | 207.6K | 27.5K | 1.14M | 38.76% | ↗ |
| 11 | 2022 | Douglas Love, Esq President and Chief Executive Officer | 568.6K | — | 277.6K | 2.38M | 345.4K | 8.0K | 3.58M | 74.26% | ↗ |
| 12 | 2022 | Douglas Love, Esq. President Chief Executive Officer | 568.6K | — | 277.6K | 2.38M | 345.4K | 8.0K | 3.58M | 74.26% | ↗ |
| 13 | 2022 | Ted Yednock, Ph.D. Executive Vice President and Chief Innovation Officer | 443.5K | — | 123.4K | 692.8K | 192.3K | 25.1K | 1.48M | 55.26% | ↗ |
| 14 | 2022 | Jennifer Lew Executive Vice President and Chief Financial Officer | 435.3K | — | 123.4K | 692.8K | 188.9K | — | 1.44M | 56.67% | ↗ |
| 15 | 2022 | Michael Overdorf Executive Vice President and Chief Business Officer | 391.0K | — | 123.4K | 692.8K | 169.3K | 20.2K | 1.40M | 58.44% | ↗ |
| 16 | 2021 | Douglas Love, Esq President and Chief Executive Officer | 533.9K | — | — | 7.23M | 297.1K | 7.2K | 8.07M | 89.61% | ↗ |
| 17 | 2021 | Douglas Love President and Chief Executive Officer | 533.9K | — | — | 7.23M | 297.1K | — | 8.06M | 89.69% | ↗ |
| 18 | 2021 | Larry Mattheakis Executive Vice President and Chief Scientific Officer | 104.8K | 150.0K | — | 3.00M | 41.6K | — | 3.30M | 91.01% | ↗ |
| 19 | 2021 | Ted Yednock EVP and Chief Innovation Officer | 416.8K | — | — | 2.56M | 169.1K | 28.7K | 3.17M | 80.63% | ↗ |
| 20 | 2021 | Sanjay Keswani Former Executive Vice President and Chief Medical Officer | 430.2K | — | — | 2.56M | 173.9K | — | 3.16M | 80.90% | ↗ |
| 21 | 2021 | Jennifer Lew Executive Vice President and Chief Financial Officer | 404.6K | — | — | 2.56M | 164.4K | — | 3.13M | 81.81% | ↗ |
| 22 | 2021 | Michael Overdorf Executive Vice President and Chief Business Officer | 372.1K | — | — | 2.56M | 151.4K | — | 3.08M | 83.02% | ↗ |
| 23 | 2020 | Douglas Love President and Chief Executive Officer | 446.0K | — | — | 3.89M | 263.7K | — | 4.60M | 84.58% | ↗ |
| 24 | 2020 | EVP Chief Business Officer | 153.5K | — | — | 3.10M | 55.6K | — | 3.31M | 93.69% | ↗ |
| 25 | 2020 | Ted Yednock EVP and Chief Innovation Officer | 364.3K | — | — | 1.81M | 161.2K | — | 2.34M | 77.53% | ↗ |
| 26 | 2020 | EVP Chief Scientific Officer | 364.3K | — | — | 1.81M | 161.2K | — | 2.34M | 77.53% | ↗ |
| 27 | 2020 | Sanjay Keswani Former Executive Vice President and Chief Medical Officer | 396.0K | — | — | 639.9K | 169.6K | — | 1.21M | 53.08% | ↗ |
| 28 | 2019 | Douglas Love President and Chief Executive Officer | 395.5K | — | — | 2.84M | 151.2K | — | 3.39M | 83.87% | ↗ |
| 29 | 2019 | Sanjay Keswani Former Executive Vice President and Chief Medical Officer | 205.8K | — | — | 1.24M | 68.9K | 101.3K | 1.62M | 76.79% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Douglas Love | Chief Executive Officer, President & Director | 1M | male |
| Dean R. Artis | Chief Scientific Officer & Executive Vice President | 797.4K | — |
| Ted Yednock | Executive Vice President, Chief Innovation Officer & Chairman of the Scientific Advisory Board | 737.8K | — |
| Jamie Dananberg | Executive Vice President & Chief Medical Officer | 715.2K | — |
| Jennifer Lew | Executive Vice President, Chief Financial Officer & Corporate Secretary | 700.0K | female |
| Michael Overdorf | Executive Vice President & Chief Business Officer | 580.5K | male |
| Lloyd Clark | Senior Vice President of Ophthalmology Strategy & Innovation | — | — |
| Shikhar Agarwal | Senior Vice President & Head of Commercial | — | male |
| Sunil Mehta | Senior Vice President of Medical Affairs | — | — |
| Henk-Andre Kroon | Senior Vice President of Translational Medicine | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ANNX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
